{
    "nct_id": "NCT00911807",
    "title": "A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",
    "status": "COMPLETED",
    "last_update_time": "2009-06-04",
    "description_brief": "The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters \\[ml\\]), Aricept (10 miligrams \\[mg\\]), and a combination of both treatments on cognitive performance and global function in patients with probable Alzheimer's Disease (AD). It should also be assessed if the treatments have a positive effect on activities of daily living and neuropsychiatric symptoms.\n\nOral treatment with Aricept or Placebo was given once daily throughout the study. Intravenous treatment with Cerebrolysin or Placebo was given once daily for 5 days per week during week 1 to 4 and during week 13 to 16 of the study. During the study patients had six visits at the hospital for evaluation.",
    "description_detailed": "Endogenous neurotrophic factors, also called neurotrophins, are signaling molecules in various cellular pathways and allow proper neuronal function, survival and regeneration. Sufficient supply is therefore regarded as a pre-requisite for neuronal maintenance but sudden or chronic pathological changes result in an imbalance of this regulatory system.\n\nCerebrolysin is a peptide preparation acting in a similar way like endogenous neurotrophic factors. Due to its pleiotropic effects - neuroprotection, neuronal survival, neuroplasticity and neurogenesis -, Cerebrolysin is regarded as potential therapeutic tool in complex diseases like stroke or dementia. In contrast to naturally occurring neurotrophic factors, neuropeptides of Cerebrolysin enter the brain parenchyma by crossing the blood-brain barrier after peripheral (intravenous \\[IV\\]) administration.\n\nAnother treatment approach for Alzheimer's disease targets the cholinergic system to increase cortical acetylcholine. One of these drugs is the anticholinesterase donepezil (Aricept). However, anticholinesterases seem to provide only symptomatic benefit for a limited period and not to influence the progression of the disease. In view of the different mechanisms of action and clinical profile of Cerebrolysin and Aricept, a combination therapy of both may provide synergistic treatment effects. The combination of a treatment targeting the neurotrophic axis (Cerebrolysin) with a treatment to improve cholinergic neurotransmission (Aricept) can arguably be expected to provide additional benefits to AD patients.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Patients were excluded from the trial before assignment to groups when not all inclusion criteria were met or when exclusion criteria were applicable.",
            "recruitmentDetails": "Dates of recruitment period: 18-OCT-2004 - 29-OCT-2007 Type of location: hospital (La Coruna), institutions specialized on cognitive disorders (Granada, Malaga)",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Cerebrolysin + Donepezil"
                },
                {
                    "id": "FG001",
                    "title": "Cerebrolysin"
                },
                {
                    "id": "FG002",
                    "title": "Donepezil"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "72"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "70"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "75"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "55"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "52"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "52"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "17"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "18"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "23"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Death",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "9"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "10"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "7"
                                }
                            ]
                        },
                        {
                            "type": "Organizational reasons",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Cerebrolysin + Donepezil"
                },
                {
                    "id": "BG001",
                    "title": "Cerebrolysin"
                },
                {
                    "id": "BG002",
                    "title": "Donepezil"
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "72"
                        },
                        {
                            "groupId": "BG001",
                            "value": "70"
                        },
                        {
                            "groupId": "BG002",
                            "value": "75"
                        },
                        {
                            "groupId": "BG003",
                            "value": "217"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0.0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "24.0"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "63"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "61"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "69"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "193.0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.5",
                                            "spread": "8.3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "75.1",
                                            "spread": "7.6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "76.0",
                                            "spread": "7.7"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "75.2",
                                            "spread": "7.9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "60"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "51"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "58"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "169.0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "48.0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Spain",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "70"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "75"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "217.0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28",
                    "description": "The ADAS-cog+ is a validated, widely used, 14 item psychometric instrument for testing cognitive functions with increased sensitivity in detecting changes in milder patients compared to the original ADAS-cog. It has a maximum score of 85 with a higher score indicating impairment and was assessed by a qualified neuropsychologist.",
                    "populationDescription": "Analysis was intention to treat",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "points on a scale",
                    "timeFrame": "baseline and week 28",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Cerebrolysin + Donepezil"
                        },
                        {
                            "id": "OG001",
                            "title": "Cerebrolysin"
                        },
                        {
                            "id": "OG002",
                            "title": "Donepezil"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "67"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "64"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "66"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.348",
                                            "spread": "5.993"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.711",
                                            "spread": "7.500"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-1.246",
                                            "spread": "6.147"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001",
                                "OG002"
                            ],
                            "groupDescription": "The null-hypothesis stated no differences between the three treatment groups regarding the mean change from baseline in ADAS-cog+ at week 28. A sample size of approximately 60 evaluable patients per treatment arm was estimated to allow for the detection of a significant group difference of two points in ADAS-cog+ week 28 change score (standard deviation \\[SD\\] 3.3) between the three groups with a power of \\> 80% and a probability level of alpha = 0.05 (two-sided).",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.6348",
                            "pValueComment": "ANCOVA F-test. The study was designed to show significant differences in each of the two primary variables. No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.",
                            "statisticalMethod": "ANCOVA",
                            "statisticalComment": "ANCOVA with the week 28 ADAS-cog+ change score as dependent variable and the ADAS-cog+ baseline score as a covariate.",
                            "paramType": "Mean Square (Factor Treatment)",
                            "paramValue": "19.59"
                        },
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.5830",
                            "pValueComment": "No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.",
                            "statisticalMethod": "t-test, 2 sided",
                            "statisticalComment": "Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.630",
                            "ciPctValue": "95",
                            "ciLowerLimit": "-2.891",
                            "ciUpperLimit": "1.630"
                        },
                        {
                            "groupIds": [
                                "OG000",
                                "OG002"
                            ],
                            "groupDescription": "Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.3434",
                            "pValueComment": "No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.",
                            "statisticalMethod": "t-test, 2 sided",
                            "statisticalComment": "Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-1.080",
                            "ciPctValue": "95",
                            "ciLowerLimit": "-3.324",
                            "ciUpperLimit": "1.163"
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG002"
                            ],
                            "groupDescription": "Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.6962",
                            "pValueComment": "No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.",
                            "statisticalMethod": "t-test, 2 sided",
                            "statisticalComment": "Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.450",
                            "ciPctValue": "95",
                            "ciLowerLimit": "-2.719",
                            "ciUpperLimit": "1.819"
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Clinical Interview-based Impression of Change (CIBIC+) Score",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline for ADAS-COG+",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16"
                },
                {
                    "type": "SECONDARY",
                    "title": "ADAS-COG+ Responders",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline for Original ADAS-COG",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "CIBIC+ Score",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16"
                },
                {
                    "type": "SECONDARY",
                    "title": "CIBIC+ Responders",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Clinical Interview-based Impression of Severity (CIBIS+) Score",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "week 4, 12, 16, 28"
                },
                {
                    "type": "SECONDARY",
                    "title": "Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])",
                    "reportingStatus": "NOT_POSTED",
                    "timeFrame": "Baseline, week 4, 12, 16, 28"
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Cerebrolysin + Donepezil",
                    "seriousNumAffected": 1,
                    "otherNumAffected": 45
                },
                {
                    "id": "EG001",
                    "title": "Cerebrolysin",
                    "seriousNumAffected": 1,
                    "otherNumAffected": 40
                },
                {
                    "id": "EG002",
                    "title": "Donepezil",
                    "seriousNumAffected": 2,
                    "otherNumAffected": 46
                }
            ],
            "seriousEvents": [
                {
                    "term": "Pyrexia",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Pulmonary embolism",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Hip fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Respiratory tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Respiratory failure",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 68
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Dyspepsia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 9,
                            "numAffected": 9,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Dysthymic disorder",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Anorexia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Confusional state",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 68
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 10.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 65
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 68
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Dr. Philipp Novak",
                "organization": "EBEWE Pharma",
                "email": "philipp.novak@ebewe.com",
                "phone": "01143-7665-8123",
                "phoneExt": "733"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "Cerebrolysin",
        "Donepezil (Aricept)"
    ],
    "placebo": [
        "Intravenous placebo (for Cerebrolysin)",
        "Oral placebo (for Aricept/donepezil)"
    ],
    "explanation_target": [
        "Reason: The trial compares Cerebrolysin (IV, a porcine brain\u2013derived neurotrophic peptide preparation) and Aricept (donepezil, an oral acetylcholinesterase inhibitor) and their combination with placebos, with primary outcomes focused on cognition and global function. Donepezil is a symptomatic cholinergic (cognitive-enhancing) agent rather than a biologic that specifically targets amyloid or tau pathology; Cerebrolysin is described in the literature as a neurotrophic/neuroprotective peptide preparation that improves cognition and global outcomes in AD trials rather than acting as a targeted anti-amyloid or anti-tau biologic. \ue200cite\ue202turn1search0\ue202turn0search2\ue201",
        "Act: Extracted key details from the trial description and literature: Cerebrolysin \u2014 porcine brain\u2013derived neuropeptide preparation with neurotrophic/neuroprotective effects and prior randomized AD trials showing cognitive/global benefit. \ue200cite\ue202turn0search2\ue202turn0search6\ue201 Donepezil (Aricept) \u2014 a reversible centrally acting acetylcholinesterase inhibitor used to improve cognition in mild\u2013moderate AD (10 mg dose used in this trial). \ue200cite\ue202turn1search0\ue202turn1search4\ue201 The published randomized trial comparing Cerebrolysin, donepezil, and combination in mild-to-moderate AD (the study described) reports cognitive and global outcome improvements with Cerebrolysin and with combination therapy; primary focus is symptomatic/cognitive endpoints. \ue200cite\ue202turn0search0\ue201",
        "Reflect: Classification choice \u2014 'cognitive enhancer' \u2014 is supported because both interventions are given to improve cognitive performance and global clinical function rather than being biologics or small molecules designed to selectively target core AD pathologies (amyloid or tau). Although Cerebrolysin is a biologic-derived product, it is not a targeted anti-amyloid or anti-tau therapeutic as defined in the 'disease-targeted biologic' category; its mechanism is neurotrophic/neuroprotective and broadly pro-plasticity, aligning it with symptomatic/cognitive enhancement in the context of this trial. (If the classification rule instead treated any biologic origin agent as a 'disease-targeted biologic' irrespective of target, this would be ambiguous \u2014 but per the provided category definitions, the emphasis is on agents targeting Alzheimer\u2019s pathology such as amyloid or tau.) \ue200cite\ue202turn0search8\ue202turn0search4\ue201",
        "Web search results (key sources used): 1) PubMed entry for the randomized trial comparing Cerebrolysin and donepezil (trial abstract, endpoints and results). \ue200cite\ue202turn0search0\ue201 2) Review and clinical trials summaries describing Cerebrolysin as a porcine brain\u2013derived neuropeptide preparation with neurotrophic/neuroprotective properties and cognitive/global benefits in AD. \ue200cite\ue202turn0search2\ue202turn0search6\ue201 3) Mechanism and pharmacology summaries for donepezil (Aricept) showing it is a centrally acting reversible acetylcholinesterase inhibitor used to improve cognition in AD. \ue200cite\ue202turn1search0\ue202turn1search4\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial tests two distinct interventions with different biological mechanisms: donepezil is a symptomatic cholinergic agent (a centrally acting, reversible acetylcholinesterase inhibitor) intended to enhance neurotransmission, while Cerebrolysin is a porcine brain\u2013derived neuropeptide preparation with neurotrophic/neuroprotective actions (mimicking endogenous neurotrophic factors and enhancing neuroplasticity). These map to different CADRO categories (Donepezil \u2192 D) Neurotransmitter Receptors; Cerebrolysin \u2192 L) Growth Factors and Hormones and/or M) Synaptic Plasticity/Neuroprotection), so the overall trial has multiple targets and is best classified as multi-target. \ue200cite\ue202turn1search0\ue202turn0search5\ue201",
        "Act: Extracted details from the trial description and literature: - Donepezil (Aricept): reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine and improves cognition in AD (symptomatic/cholinergic mechanism). \ue200cite\ue202turn1search0\ue202turn1search6\ue201 - Cerebrolysin: an intravenous, porcine brain\u2013derived peptide/neuropeptide preparation that mimics neurotrophic factors, promotes neuroprotection/neuroplasticity, and has shown cognitive/global benefits in randomized AD trials (including a head-to-head/comparison trial with donepezil and combination therapy). \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Reflect: Classification choice \u2014 'R) Multi-target' \u2014 is appropriate because the trial deliberately compares two agents acting through different biological pathways (cholinergic neurotransmission vs. neurotrophic/neuroprotective mechanisms). If asked to label each drug separately, Donepezil would fall under D) Neurotransmitter Receptors and Cerebrolysin most closely aligns with L) Growth Factors and Hormones and/or M) Synaptic Plasticity/Neuroprotection; because both are tested together in the same trial, CADRO guidance indicates 'R) Multi-target'. The web sources used to support mechanisms and trial results are listed below. \ue200cite\ue202turn0search0\ue202turn0search5\ue202turn1search0\ue201",
        "Web search results (key sources used): 1) Randomized trial comparing Cerebrolysin, donepezil, and combination therapy (primary endpoints cognitive and global outcomes). \ue200cite\ue202turn0search0\ue201 2) Reviews and experimental summaries describing Cerebrolysin as a porcine brain\u2013derived neuropeptide preparation with neurotrophic/neuroprotective effects and clinical trial evidence in AD. \ue200cite\ue202turn0search5\ue202turn0search6\ue201 3) Study showing Cerebrolysin (and combination with donepezil) increases serum BDNF associated with cognitive improvement. \ue200cite\ue202turn0search2\ue201 4) Mechanism and prescribing information for donepezil (Aricept): reversible centrally acting acetylcholinesterase inhibitor used to improve cognition in AD. \ue200cite\ue202turn1search0\ue202turn1search6\ue201"
    ]
}